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during the drug discovery pathway is advantageous to minimize costs and improve patient safety. However, current cellular
models are sub-optimal. This review addresses the potential use of pluripotent stem cells in the generation of hepatic cell
lineages. It begins by highlighting the scale of the problem faced by the pharmaceutical industry, the precise nature of
drug-induced liver injury and where in the drug discovery pathway the need for additional cell models arises. Current research is
discussed, mainly for generating hepatocyte-like cells rather than other liver cell-types. In addition, an effort is made to
identify where some of the major barriers remain in translating what is currently hypothesis-driven laboratory research into
meaningful platform technologies for the pharmaceutical industry.
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The clinical translation of human pluripotent stem cell (PSC)
research into cell therapy for patients has rightly captured
the public's imagination for how healthcare might enjoy
major advances in the 21st century. An alternative, yet
similarly profound, opportunity for clinical benefit is the use
of differentiated ‘non-clinical grade’ cells to screen the
toxicity of putative new drugs in pharmaceutical develop-
ment. In this review, we address the use of PSCs in pre-
clinical hepatotoxicity screening. At present, most work in
this area employs human embryonic stem cells (ESCs)
differentiated towards hepatocytes, but this may be
supplanted by the use of induced (i) PSCs. Previous articles
in stem cell journals have focused on reviewing the relative
merits of different differentiation protocols as has been
described recently for the pancreatic beta cell (Van Hoof et
al., 2009). Here, we update in this area, but also focus on the
perspective of the pharmaceutical industry and their
requirements for a pre-clinical model of toxicity testing.
The considerations for screening new chemical entities
(NCEs) during the drug discovery pathway stretch far beyond
whether we can generate the perfect hepatocyte in the
research laboratory.The scale and importance of drug-induced liver injury
The potential value of applying human PSC research to
hepatotoxicity screening of NCEs should not be understated.
Unexpected toxicity and adverse drug events post-licensing are
leading causes of compound attrition and product withdrawal,
with up to 30% of compound failures occurring due to toxicity
and clinical safety issues (Kola and Landis, 2004). In a series of
high-profile cases where approved drugs have been withdrawn
from the market, 50% were due to drug-related hepatotoxicity
(Lee, 2003). A recent study found that 6.2% of all UK hospital
admissions were related to adverse drug reactions (ADRs)
(Pirmohamed et al., 2004). ADRs can be regarded as a
significant burden on public health, with a 0.15% mortality
rate and high economic costs associated with hospitalization ofpatients (Pirmohamed et al., 2004). One of the most common
causes of toxicity-induced ADRs is drug-induced liver injury
(DILI), however, the underlying mechanisms of tissue damage
are complex, multi-dimensional, incompletely understood and
not fully amenable to testing in cell culture systems (Goldring
et al., 2006) (Fig. 1). Many drugs form reactivemetabolites that
can covalently bind to cellular macromolecules, and initiate
and propagate liver injury (Usui et al., 2009). DILI caused
through organelle dysfunction directly in human hepatocytes,
for example mitochondrial (Labbe et al., 2008; Rachek et al.,
2009) or endoplasmic reticular (ER) dysfunction (Lawless et al.,
2008), is more amenable to testing in cell culture systems.
Mitochondrial dysfunction is an important mechanism whereby
pharmaceuticals can trigger serious liver injury through
disruption of mitochondrial energy production and/or release
of pro-apoptotic proteins into the cytoplasm, ultimately
resulting in hepatocyte necrosis or apoptosis and cytolytic
hepatitis (Labbe et al., 2008). Alternatively, mitochondrial
dysfunction can lead to steatosis and steatohepatitis whichmay
progress to cirrhosis (Labbe et al., 2008). Redox perturbation
induced by drug exposure may lead to ER stress (Frosali et al.,
2009). ER dysfunction may also be initiated by protein overload
or mis-folding and lead to apoptosis. The ‘suicide’ option of
apoptosis is the last line of defense for the hepatocyte. Prior to
this, complex adaptations are possible (Fig. 2), which serve to
reinforce the dynamic, complex phenotype of the hepatocyte
in response to chemical stress.
Taken together, these multi-faceted risks associated with
NCEs place high demands for effective and predictive toxicity
screening models. The specific attributes of these models,
including the potential use of human PSCs, also need to be
tailored to the timing of their application during the drug
discovery pathway.
The drug discovery pathway - the need for better
cell models
In recent years, the pharmaceutical industry has faced
considerable challenges related to the reduced productivity of
NCEs, increased production costs, long research and develop-
ment timelines, and high attrition rates. Factoring in these
Figure 1 Liver injury. The liver is the primary organ formetabolic biotransformation of xenobiotics, including drugs, and is consequently a
frequent target for a variety of hepatotoxic insults. Chemically-mediated toxicity can affect any cell-type andmimic any naturally occurring
disease process. Frequently, the initial toxic insult is followed by involvement of the immune systemwith a resulting inflammatory reaction.
6 M.A. Baxter et al.issues, the cost of bringing a drug tomarket is thought to be USD
$0.9-1.7 billion (Kola, 2008). One study, published in 2004,
analyzed the rate of success for registering products compared
to the number of ‘first-in-man’ studies over a decade (1991-
2000) for the 10 largest US and European pharmaceutical
companies (Kola and Landis, 2004). On average, the success rate
was just 11% with the vast majority of failures occurring in late
Phase III trials or at registration. These late failures are
associated with enormous financial costs. The US Food and
Drugs Administration (FDA) felt that stagnation in the drug
discovery pathway was so serious that it commissioned a reportFigure 2 The multi-tiered defence response against chemically-
defense responses adopted by the liver in reaction to increasing severity
expression of antioxidant proteins and lowmolecular weight scavengers
transporters. Subsequently these defences are bolstered through a tran
orchestrated through the factor Nrf2. Finally, the cell is scheduled to u
death, which carries with it the added risk of an inflammatory responsein 2004 to analyze pipeline problems (http://www.fda.gov/oc/
initiatives/criticalpath/whitepaper.htm).
Traditionally, the bottleneck in the discovery pathway was
thought to be the identification of hit compounds based on,
amongst other criteria, assay performance, analyses of struc-
ture-activity relationships, potency and dose response effects
(Fig. 3). However, as in silico technologies for high-throughput
screening have improved, attrition rates have not, indicating
that the bottleneck has shifted downstream to the phase of
‘lead optimization’ (Bleicher et al., 2003). Lead optimization
aims to improve the attributes of a compound as a candidateinduced toxicity within the liver. Diagram to show the range of
of chemical stress. Initial defence is provided through constitutive
(e.g. glutathione), as well as phase II drugmetabolizing enzymes and
scriptionally induced up-regulation of defence proteins, principally
ndergo apoptotic self-destruction as an alternative to necrotic cell
.
Figure 3 The drug discovery pathway. Schematic overview of both the pre-clinical and clinical phases of drug development. ESC-derived
liver cells are highly desirable as cell models during lead optimization.
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converted to its active form after administration) by altering
chemical structure, as well as considering absorption, distribu-
tion, metabolism and elimination properties. Critically, lead
optimization also involves assessment of toxicity in a range of
tests. Animal studies, both in vitro and in vivo, are a useful tool
in the drug development process and a number of species,
including rodents, dog and monkey, are commonly used for
testing potential toxicity of NCEs before the first dose is
administered in man. However, species differences in the
activities of orthologous drugmetabolizing enzymes, whichmay
produce hepatotoxic metabolites in a species-specific manner
means that extrapolation to man from such models must be
undertaken with caution (Martignoni et al., 2006). Between
synthetic in vitro assays of cytochrome P450 (CYP) activity and
animal studies, the FDA report identified a pressing need for
better in vitro cell models to broaden understanding of the
biochemical and genetic basis of DILI, and to develop predictive
liver toxicity biomarkers for hepatotoxicity screening; hence,
the interest in human PSC research. The goals are two-fold and
interlinked: to demonstrate the safety and effectiveness of
potential lead compounds in faster time-frames, with more
certainty, at lower costs; and to identify unfavorable toxicity
profiles during lead optimization thereby reducing attrition
rates in late-stage development.
Cellular models of hepatotoxicity—what is the
standard for pluripotent stem cell research?
Requirements for effective hepatotoxicity screening
The liver is composed of hepatocytes, making up 70% of liver
mass, and other cell-types such as Kupffer cells, stellate cells,biliary epithelial cells, endothelial cells and, potentially,
infiltrating immune cells. The organ has a precise tissue archi-
tecture (Fig. 4), which, along with the characteristics of the
composite cell population, contributes to the toxicity or
resolution of a particular chemical insult (Liu et al., 2004;
Imaeda et al., 2009) (Fig. 1). Therefore, cell models for
hepatotoxicity should ideally incorporate all these components
and faithfully represent themyriad functions a liver performs in
vivo. As a priority, the model's capacity to metabolize
xenobiotics is paramount, which requires expression of CYP
enzymes that are inducible by various liver-enriched nuclear
receptors and transcription factors (Goldringet al., 2004; Itoh et
al., 1997; Itoh et al., 1995). CYPs are of particular importance in
the generation of hepatotoxicants (Goldring et al., 2006;
Antoine et al., 2008), however, not all hepatotoxicity is
metabolism-mediated (Iwanaga et al., 2007). Amongst the
first consequences of chemical and oxidative insult is NFκB-
induced cytokine release (Bowie and O'Neill, 2000). Another
liver function essential to the resolution of toxic assault is the
ability to process and eliminate any reactive intermediates
through conjugation (Bock et al., 1987) or transport (Szakacs
et al., 2008). Therefore, in addition to expressing hepatic
enzymes (Table 1), model cells must have commensurate pools
of the cognate factors and co-factors.Human hepatocellular carcinoma cell lines
The availability and ease-of-culture of hepatocellular carcino-
ma-derived cell lines have made their application to toxicity
studies an attractive proposition, but in reality their utility is
hindered by incomplete and abnormal metabolic and transport
pathways (Castell et al., 2006). The major CYPs may be poorly
expressed or absent and other isoforms associated with tumour
Figure 4 The human liver and its composite cell-types. Diagramto showtheorganizationof different cell-types in the liver. Hepatocytes
are arranged as anastomosing plates, one cell thick. Biliary epithelial cells line the bile duct and contribute to bile secretion. Bile collects in
canaliculi which run along the surface of hepatocytes. Hepatic sinusoids are small blood vessels lined by discontinuous endothelial and Kupffer
cells (specialized macrophages of hematopoietic origin). The sinusoids are separated from the hepatocytes by the space of Disse, which
contains stellate cells. In the absence of liver injury, stellate cells at this location are considered quiescent but are thought to activate in
response to inflammatory stimuliwhen theymigrate into the liver parenchymaanddeposit theexcessiveextracellularmatrix characteristic of
liver fibrosis.
8 M.A. Baxter et al.cells can be over-expressed, making extrapolation of their in
vitro metabolism profiles to in vivo liver function potentially
misleading. Nevertheless, they can be useful in the study of
particular enzyme isoforms following transient or stable
transfection (Goldring et al., 2006; Aoyama et al., 2009).
Recently there have been reports of a novel cell line (HepaRG)
which can be expanded in an undifferentiated state and on
reachingconfluencecanbedifferentiated intobothhepatocyte-
and biliary-like cells (Guillouzo et al., 2007; Parent et al., 2004).
The former cells express a good complement ofmRNAs encoding
drug metabolizing proteins, demonstrate CYP3A4, CYP1A2 and
UDP-glucuronosyltransferase activity comparable to primary
human hepatocytes (Kanebratt and Andersson, 2008) and have
been suggested as suitable for chronic toxicity and genotoxic
studies (Josse et al., 2008). However, the clonal nature makes
the cell line representative of only one genotype.Primary human hepatocyte culture
Isolated primary human hepatocytes are the current ‘gold-
standard’ in vitro model as they express the entire
complement of hepatocyte drug metabolizing enzymes and
transporters (Hewitt et al., 2007). Dissociation and culturing
purified hepatocytes in monolayer obviously compromises
model complexity compared to the native organ, however,
overlaying extracellular matrix enhances maintenance of the
differentiated hepatocyte phenotype, including cell polari-
ty, for days or weeks (Lecluyse, 2001; Moghe et al., 1996).
Co-culture of hepatocytes with epithelial cells (Rogiers and
Vercruysse, 1993), stellate cells (Riccalton-Banks et al.,
2003) and pancreatic cells (Kaufmann et al., 1999) has also
been investigated as a step towards designing systems with
enhanced liver complexity. Despite this, there are manyissues that remain problematic with the use of primary
human hepatocytes. Supply is scarce as relatively small
numbers can be isolated from tissue derived from planned
surgical resections. Large numbers of hepatocytes may
occasionally become available from whole organs deemed
unsuitable for transplantation, but by nature this tissue is
often of poorer quality and unpredictable in supply. Such
issues have stimulated research on cryopreservation (Terry
and Hughes, 2009), which has made progress, although there
is inevitable variation between batches (Roymans et al.,
2004). As a toxicity screening platform for the pharmaceu-
tical industry, batch-to-batch consistency and ability to ship
cryopreserved cells without loss of function are important.
Even in optimised culture systems, hepatocytes still lose the
differentiated phenotype that is essential for meaningful
study of drug metabolism and toxicity (Elaut et al., 2006).
Dedifferentiation includes losing the ability of certain CYPs
and phase II genes to be induced by reference compounds
(Park et al., 1996), in part due to the activation of stress
signaling pathways and the generation of nitric oxide (Sidhu
et al., 2004; Lopez-Garcia, 1998; Rodriguez-Ariza and
Paine,1999; Vernia et al., 2001; Aitken et al., 2008; Olsavsky
et al., 2007; Page et al., 2007). Nitrite levels are inversely
correlated to CYP levels and activity; the latter decline with
increased nitrosylation, haem loss and degradation (Lopez-
Garcia, 1998; Vernia et al., 2001; Aitken et al., 2008). Nitric
oxide-producing stimuli also reduce the levels of liver
enriched nuclear factors and nuclear receptors (Fang
et al., 2004; Beigneux et al., 2002).
Differential pharmacodynamic and toxic responses in vivo
and in vitro arise from the great diversity of metabolic
phenotypes in human populations. These may be genetic,
environmental, dietary, occupational, disease-related, or
drug-induced and explain, in large part, the differences
Table 1 Characteristics for defining human PSC-derived hepatocyte-like cells.
A Liver cell
type
Gene % ESTs Conflicting expression in: Discriminatory genes
Fetal hepatoblast AFP 21 Fetal heart, extraembryonic
endoderm
MLC2V (fetal heart), MUC1
(fetal lung)
ALB 63 Mature hepatocyte, fetal lung
TDO2 58 Fetal heart, fetal lung
Mature hepatocyte OATP2 89 Highly specific MUC1 (fetal and mature lung), AFP
(fetal liver, EEE), MLC2V (fetal heart),
HAND2 (ciliary ganglion)
ALB 63 Fetal heart, fetal lung
AAT 93 Mature lung
TDO2 58 Fetal heart, fetal lung
TAT 85 Ciliary ganglion
Biliary cell/
cholangiocyte
KRT17 b0.1 Bronchial epithelium KRT14 (bronchial epithelium), ACPP
(prostate), MUC1 (fetal lung), PDX1
(fetal pancreas), SIX2 (fetal kidney)
KRT19 3 Many other cell-types
HNF1B 8 Fetal kidney, fetal pancreas
B Functional assessment Method overview Specificity Reference
Glycogen storage Periodic acid–Schiff staining Useful but also occurs in muscle and
undifferentiated ESCs
(Gomori, 1952)
Urea production Measurement of synthesis and
excretion by detection in cell-free
conditioned medium
Specific hepatocyte function (Pless et al., 2006)
Albumin secretion Measurement of protein in cell-
free conditioned medium
Relatively insensitive test—other
functional properties are lost before
albumin secretion
(Dich et al.,
1987)
Low density lipoprotein
(LDL) uptake and
metabolism
Detection of labelled intracellular
uptake and degradation
Useful but also occurs in vascular
endothelial cells and macrophages
(Voyta et al., 1984)
Indocyanine green (ICG) Hepatocytes in culture take up and
secrete ICG dye over 6 h
Difficult to apply to cultured cells due
to lack of functional bile excretion
system in vitro
(Pless et al., 2006;
Yamada et al., 2002)
C CYP Substrate Inducer
1A1 theophylline, polycyclic aromatic hydrocarbons (PAH) PAH, e.g., benzopyrene
1A2 caffiene, melatonin, warfarin rifampicin, phenobarbital
2A6 coumarin, nicotine, quinoline, valproic acid, paracetamol rifampicin, phenobarbital,
dexamethasone
2B6 nictoine, bupropion, cyclophosphamide, efavirenz clotrimazole, rifampicin,
phenobarbital
2C8 ibuprofen, paclitaxel, cerivastatin rifampicin, carbamazepine
2C9 warfarin, phenytoin, linoleic acid, rosiglitazone, tolbutamide rifampicin, carbamazepine,
hyperforin
2C19 amitriptyline, diazepam, phenobarbital, lansoprazole rifampicin, hyperforin,
prednisone
2D6 debrisoquine, codiene, timolol, flecainide, dextromethorphan piperidines, dexamethasone,
rifampicin
2E1 ethanol, paracetamol, halothane, toluene acetone, ethanol
3A4 testosterone; glutathione transferases – 1-chloro-2,4-dinitrobenzene,
UDPGT – 4-methylumbelliferone; OATP –ICG
rifampicin, phenobarbital,
hyperforin, carbamazepine
A. Genes expressed in human fetal hepatoblast, mature hepatocyte and biliary epithelial cells to discriminate these cell-types from
others that might arise during PSC differentiation. ‘% ESTs’ refers to the percentage of expressed sequence tags derived from liver in
the Unigene database; high values indicate expression that is restricted to liver. No gene is uniquely expressed in liver, however, the
expression of ‘discriminatory genes’ should not be detected in fetal hepatoblast, mature hepatocyte or biliary epithelial cell
respectively. B. Functional analyses that can be undertaken to assess human PSC-derived hepatocyte-like cells in comparison to freshly
isolated human primary hepatocytes. C. CYP enzymes expressed in mature hepatocytes along with their metabolic substrates and
reference compounds known to induce their expression and / or activity.
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10 M.A. Baxter et al.demonstrated by pools of hepatocytes isolated from differ-
ent donors (Ponsoda et al., 2001). This genotype-dependent
expression of important CYPs, such as CYP3A isoforms,
CYP1A2, CYP2A6, CYP2B6, CYP2D6, and several CYP2C
isoforms, would cause highly variable toxicity readouts for
NCEs. Ideally, this genotypic diversity needs to be reflected
in banks of primary hepatocytes or equivalent depositories of
PSC-derived cells (Ingelman-Sundberg et al., 2007). Not all
variability in gene expression is due to sequence differences;
the expression of microRNAs (miRNA) and gene methylation
are additional control mechanisms that may play a role in the
severe down-regulation of CYP expression in isolated and
primary cultured cells, and cell lines (Ingelman-Sundberg et
al., 2007; Gomez and Ingelman-Sundberg, 2009). Methyla-
tion of CpG islands in the gene promoters of several of the
most important CYPs have been identified, the transcripts
fromwhich may also be regulated by miRNAs interacting with
the 3`UTR, as is the case for CYP3A4 and CYP2B6 (Ingelman-
Sundberg et al., 2007).
Despite these problems, primary cultures of adult human
hepatocytes remain the current gold standard in human
metabolism and hepatotoxicity studies. They play a pivotal
role in drug discovery and development (Soars et al., 2009;
Soars et al., 2007) and they set the standard against which
PSC-differentiated progeny need to be judged.
Generating liver cell-types from human
pluripotent stem cells
Theoretically, PSC-derived liver cells have a number of
advantages over primary adult hepatocytes for drug testing.
They can potentially give rise to all of the composite cells of
the adult human liver, thus could provide a complexity for
toxicity screening that begins to approximate the intact
organ (Fig. 4) (Itskovitz-Eldor et al., 2000). They could also
generate liver cells at different stages of maturity; to assess
the effects of drugs at different stages of liver development.
The genetic diversity that underlies the major differences in
metabolizing genotype can also be represented by access to
different genotyped ESC or iPSC lines (Taylor et al., 2005;
Nakatsuji et al., 2008). iPSC technology has the potential to
generate liver cell-types with particular disease phenotypes,
providing disease-specific cell models for therapeutic drug
development and testing. PSCs prior to differentiation are
more available and can be cryopreserved with retention of
phenotype more readily than primary hepatocytes (Baxter et
al., 2009; David et al., 2009). A ready supply of liver cells
from a particular ESC or iPSC line would also improve
reproducibility during screening by avoiding the batch to
batch variability of primary adult hepatocytes. All these
attributes have stimulated interest that human PSCs can be
applied to drug toxicity screening during lead compound
optimization and improve understanding of the biochemical
pathways involved in human metabolism. To anticipate use
of PSC-derived hepatocyte-like cells to replace all current
pharmaceutical practices would be naïve, but their integra-
tion alongside other types of screening tests is feasible; for
instance, in helping to minimise laboratory animal usage.
The major challenge is to develop robust platforms for the
differentiation of the desired cell-types from PSCs on a scale
and practicality that improves on current practice by thepharmaceutical industry. The following sections update on
progress in this area and highlight where gaps remain.
Development of the liver
In vitro protocols for differentiating PSCs to hepatocytes draw
heavily on knowledge of how the liver normally develops and
matures during embryogenesis and the fetal period (Fig. 5).
The three germ layers of the embryo are formed during
gastrulation which begins at E6.5 in mice (Kubo et al., 2004).
During this period, epiblast cells fated to become definitive
endoderm undergo epithelial-mesenchymal transition (EMT)
at the anterior primitive streak under the influence ofWnt and
high levels of Nodal signalling (Kubo et al., 2004; Murry and
Keller, 2008; Nakanishi et al., 2009). Folding turns the flat
sheet of definitive endoderm, regulated by the transcription
factors SOX17, GATA4 and FOXA2, into a gut tube (Wells and
Melton, 1999). Hepatogenesis begins at E8.5-9 from the
ventral foregut endoderm in progenitor cells that harbour an
equal capacity to form the ventral bud of the pancreas
(Deutsch et al., 2001; Kamiya et al., 1999). Hepatic
specification of these bipotent cells is induced by dual
signalling from two adjacent mesodermal sources: fibroblast
growth factor (FGF) 1, FGF2 and FGF8 from the neighbouring
cardiacmesoderm; and bonemorphogenic protein (BMP) 2 and
BMP4 from the septum transversum (Jung et al., 1999; Chung
et al., 2008; Rossi et al., 2001). Once specified, the
hepatoblasts proliferate under autocrine signals and ones
from surrounding angioblasts, and invade the stroma of the
septum transversum (Jung et al., 1999; Lemaigre and Zaret,
2004; Matsumoto et al., 2001). They are bipotent, expressing
markers for fetal hepatocytes [e.g. hepatocyte nuclear factor
(HNF) 4α, HNF6, alpha-fetoprotein (AFP) and albumin (ALB),
and biliary epithelium (e.g. cytokeratin (KRT) 17 and KRT19)]
(Lavon and Benvenisty, 2005; Tanimizu and Miyajima, 2004)
(Fig. 5). At E10, haematopoietic cells colonize the nascent
liver bud. This induces Notch signalling, which acts to
differentiate the bipotential hepatoblasts by promoting or
inhibiting differentiation into either biliary duct epithelium or
hepatocytes respectively (Lavon and Benvenisty, 2005; Tani-
mizu and Miyajima, 2004). The haematopoietic cells also
produce the cytokine, oncostatin M (OSM), which, in combi-
nation with glucocorticoid, acts as a liver maturation factor
(Kinoshita et al., 1999). Hepatocyte growth factor (HGF) from
the septum transversum and surrounding nonparenchymal
liver cells also plays important roles over a long time course by
promoting hepatocyte proliferation, survival and maturation
(Zaret, 2000; Kamiya et al., 2001). Complete hepatocyte
maturation only occurs after birth (Kamiya et al., 2001).
Differentiating pluripotent stem cells towards
hepatocyte-like cells
Atpresent, efforts to generate hepatocyte-like cells havebeen
predominantly from ESCs rather than iPSCs, although the first
advances with the latter cell-types have recently been
published (Song et al., 2009; Sullivan et al., 2009). So far,
methods developed using ESCs have also been found broadly
applicable using iPSCs (Song et al., 2009; Gareth et al., 2010).
Various strategies have been applied, most of which aim to
simulate in vivo liver development in the in vitro setting
Figure 5 Schematic diagram representing hepatic differentiation in vivo correlated to in vitro differentiation of human
pluripotent stem cells. Liver development in vivo and hepatocyte differentiation in vitro are depicted with examples of gene
expression associated with each developmental or differentiation stage. Exogenous factors are shown that are typically added in vitro
to induce differentiation.
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corresponding characterisation studies in Table 2.
In vitro simulation of in vivo liver development
Differentiation of liver cell-types can be divided into three
steps: definitive endoderm differentiation, hepatocyte pro-
genitor specification and hepatocyte maturation (Fig. 5). In
addition, it is possible to consider three components, which
collectively form an evolving niche for differentiation: soluble
growth factors; supporting cell-types; and extracellularmatrix
(ECM).
Soluble growth factors. The first protocol to describe
differentiation of ESCs towards hepatocytes used embryoid
body (EB) formation to induce initial differentiation (Hamazaki
et al., 2001). EB formation by ESC aggregation, potentially
with subsequent plating onto adhesive substrates (such as
Matrigel or collagen) as EB outgrowth cultures (Itskovitz-Eldor
et al., 2000), serves as an in vitro mimic of gastrulation and
subsequent lineage specification. However, the differentia-
tion is random (Kubo et al., 2004; Pei et al., 2009; Soto-
Gutierrez et al., 2006; Momose et al., 2009). To prioritise
hepatocyte differentiation, cultures have been treated with
exogenous factors and the resulting hepatocyte-like cells
characterised by their gene expression profile and character-
istics (Momose et al., 2009; Duan et al., 2007) (Table 2).
Subsequent protocols have aimed to avoid the inherent
random differentiation in EB-based protocols by the direct
induction of ESCs cultured in monolayer. As a mimic for the in
vivo Nodal and Wnt signalling at the anterior end of theprimitive streak, initial definitive endoderm differentiation of
ESCs has been routinely induced byWnt3a and high concentra-
tions of Activin A (commonly 100 ng/ml) (Nakanishi et al.,
2009; Cai et al., 2007; Zhao et al., 2009). Conversely,
phosphatidylinositol 3-kinase (PI3K) is known to block endo-
derm differentiation from ESCs (D'Amour et al., 2005), such
that low serum concentrations or specific PI3K inhibitors (e.g.
LY294002) have been used alongside Activin A (Mclean et al.,
2007; Shiraki et al., 2008).
Following definitive endoderm formation, characterised
by expression of GATA4, FOXA2 and SOX17 (D'Amour et al.,
2005), hepatocyte specification has been mimicked by the
addition of FGF and BMP family members (Cai et al., 2007;
Gouon-Evans et al., 2006), to mirror the secretion of these
factors from the cardiac mesoderm and septum transversum
respectively (Chung et al., 2008; Neta Lavon, 2005). In vitro,
FGF2 or FGF4 and BMP2 or BMP4 have been added to specify
hepatocyte progenitors (Cai et al., 2007; Zhao et al., 2009;
Shiraki et al., 2008; Gouon-Evans et al., 2006).
For final maturation of hepatocyte progenitors, specialised
hepatocyte growth medium has been devised (Jasmund et al.,
2007)with a number of addedmaturation factors. These factors
typically include HGF, shown to support the expansion of fetal
hepatocytes (Kamiya et al., 2001), OSM, known to induce
differentiation and maturation of fetal hepatocytes (Kamiya
et al., 1999; Kinoshita et al., 1999) and dexamethasone, a
potent synthetic glucocorticoid, which induces the activity of
hepatocyte enzymes, such as phosphoenolpyruvate carboxyki-
nase (PEPCK), tyrosine aminotransferase (TAT) andmembers of
the CYP family (Neta Lavon, 2005; Duanmu et al., 2002).
Table 2 Summary of studies reporting the differentiation of human PSCs to hepatocyte-like cells.
Ref Differentiation
method
Characterization Liver-associated
markers
Functional assessment
EB Monolayer Co-
culture
ECM Factors
added
RT-
PCR
ICC WB FACS AFP AAT HNF4 TAT Albumin
secretion
Glycogen
storage
ICG
uptake &
excretion
LDL
uptake
CYP
activity
In vivo
transplant
Comments / limitations
(Rambhatla
et al.,
2003)
+ + M DMSO, Na
Butyrate,
HGF
+ + - - + + + - - + - - + - AFP not detected in
Na butyrate-treated
cultures.
(Lavon
et al.,
2004)
+ - FGF1,
FGF2,
BMP4,
HGF
+ + - + + - - - - - - - - - Each growth factor
added individually,
not altogether. Very
simple differentiation
protocol.
(Cai et al.,
2007)
- + MEF AA,
FGF4,
BMP2
HGF,
OSM, DEX
+ + - - + + - + + + + + + + CYP activity levels not
compared to adult
hepatocyte control.
Very low levels of liver
integration in vivo.
(Duan
et al.,
2007)
+ + C DEX + + - + + + + + + + + - + + Method relies on
spontaneous
hepatocyte ESC
differentiation and
microdissection for
hepatocyte
enrichment. Variable
TAT expression.
(Ek et al.,
2007)
- + MEF FGF2 + - + - - - + - - - - - - - No CYP activity
despite detection of
CYP transcript and
protein.
(Hay et al.,
2007)
- + M DMSO,
HGF,
OSM
+ + + - + + + - + + + - + - Low efficiency: only
foci of hepatocyte-like
cells, only 10% of
which were positive for
ICG. No positive control
for CYP activity assay.
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(Agarwal
et al.,
2008)
- + C AA,
FGF4,
HGF
OSM, DEX
+ + + + + + + - + + + - - + No data on CYP
enzyme activity levels.
Low/sporadic liver
integration and
differentiation.
(Baharvand
et al.,
2008)
- + M FGF2,
Noggin,
aFGF,
FGF4,
HGF,
DEX, OSM
+ + - + + + + + + + + + - - No expression of G6P,
marker of hepatocyte
maturation. Adult
primary hepatocytes
not used as control
in functional assays
(Chiao
et al.,
2008)
+ - FGF1 + + - + + - + - + - - - - - AFP positive cells
selected by reporter
gene expression.
Very simple
differentiation
protocol.
(Hay et al.,
2008b)
- + M AA, Na
Butyrate,
DMSO,
HGF,
OSM
+ + + + + + + + - + - - + - Low CYP protein +
activity levels
compared to adult
hepatocyte control.
(Ishii et al.,
2008)
+ + C, L
M
HGF,
BMP4,
FGF4, AA
all-trans
retinoic
acid
+ + - + - + - + - - - - - - Aim of study to
asess the affect
of extracellular
matrices on hepatic
differentiation.
No functional
tests.
(Jasmund
et al.,
2007)
- + M15
cells
AA,
FGF2,
LY294002
HGF, DEX
+ + - + + - - - + + - - + - Low efficiency: 9%
albumin positive
cells after 40 days
differentiation.
(Basma
et al.,
2009)
+ + M AA,
FGF2,
HGF
DMSO,
DEX
+ + + + + + - - + + - - + + Transplantation of
ASGR sorted
population enriched
for liver markers.
Recipients developed
adenocarcinoma.
(continued on next page) 13
G
enerating
hepatic
cell
lineages
from
pluripotent
stem
cells
for
drug
toxicity
screening
Table 2 (continued)
Ref Differentiation
method
Characterization Liver-associated
markers
Functional assessment
EB Monolayer Co-
culture
ECM Factors
added
RT-
PCR
ICC WB FACS AFP AAT HNF4 TAT Albumin
secretion
Glycogen
storage
ICG
uptake &
excretion
LDL
uptake
CYP
activity
In vivo
transplant
Comments / limitations
(Moore and
Moghe,
2009)
- + MEF DEX,
OSM,
HGF, AA,
WNT3A
+ + - + + + + - + - + - + - CYP activity levels
only compared to
undifferentiated ESC
no positive adult
primary hepatocyte
control.
(Pei et al.,
2009)
+ - fetal
liver
cell
line
AA, HGF,
OSM, DEX
+ + - - + - - - + + + - - - No data on CYP
activity levels.
Limited panel of
markers used to
characterize
hepatocytes.
(Song
et al.,
2009)
- - MEF AA,
BMP2,
FGF4,
HGF,
KGF,
OSM, DEX
+ + - - + + + - - + - - - - Very low levels of
albumin secretion,
urea synthesis,
albumin secretion
and CYP3A4 activity
in comparison to
adult hepatocytes.
(Zhao
et al.,
2009)
- + STO AA,
BMP2,
FGF4,
HGF,
OSM, DEX
+ + - + + + + + + + + + + - Albumin secretion and
CYP activity levels not
compared to adult
hepatocyte control.
In addition to abbreviations used throughout the article text, those used in the Table are: AA, activin A; C, collagen; DEX, dexamethasone; iMEFs, inactivated mouse embryonic fibroblasts; ICC,
immunocytochemistry; KGF, keratinocyte growth factor; L, laminin; M, Matrigel; Na butyrate, sodium butyrate; STO, a specific mouse embryonic fibroblast cell line; VEGF, vascular endothelial
growth factor; WB, western blot.
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15Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screeningCo-culture with supporting cell-types. Similar to the recog-
nised benefits of culturing PSCs on inactivatedmouse embryonic
feeder cells (MEFs) (Thomson et al., 1998), differentiating cells
in vitro toward hepatocytes can benefit from contact with other
cells (Fair et al., 2003). During development hepatoblasts
interact with both the cardiac and septum transversum
mesoderm; in teratomas, hepatocyte-like cells have been
observed to differentiate alongside cardiac cells (Lavon et al.,
2004). ESCs co-cultured with both embryonic chick mesoderm
(Fair et al., 2003) and a mesoderm-derived cell line (M15)
(Shiraki et al., 2008) demonstrated enhanced hepatocyte
differentiation. Other examples include the use of human non-
parenchymal liver cell lines, which have been shown to support
mature hepatocyte culture by the production of hepatocyte
mitogens (Kang et al., 2004). Similarly, Zhao and colleagues
found that ESC-derived hepatic progenitor cells could be
expanded upon murine embryonic stromal cells (Zhao et al.,
2009). Alternatively, feeder cell lines have been genetically
modified to produce specific growth factors, such as FGF2, in
order to enhance hepatocyte differentiation (Pei et al., 2009).
Extracellular matrix. It is difficult to attribute how much of
the benefit from co-culture comes from the provision of ECM
by the supporting cell-type rather than from cellular contact.
Several ECM substrates have proven beneficial. In vivo, the
liver bud expands into the collagen-rich stroma of the septum
transversum (Hamazaki et al., 2001; Agarwal et al., 2008).
Two substrates regularly used for in vitro differentiation of
hepatocyte-like cells are collagen and, arguably better (Ishii
et al., 2008), Matrigel, a proprietary matrix from BD
Biosciences, one of the constituents of which is collagen
(Kleinman and Martin, 2005). A natural extension of this work
has been the development of 3D scaffolds, which potentially
improve mimicry of the in vivo developmental microenviron-
ment. Collagen scaffolds have supported the generation of
functional hepatocyte-like cells differentiated both directly
from ESCs and via EBs (Baharvand et al., 2006; Imamura et al.,
2004).
Epigenetic manipulation of hepatocyte-like differentiation
from embryonic stem cells
The first protocol to differentiate hepatocyte-like cells from
human ESCs utilised selection of hepatocyte progenitor cells
by the histone deacetylase inhibitor, sodium butyrate, which
caused massive cell death of presumptive non-hepatic cells
and was thought to help maintain CYP activity (Rambhatla et
al., 2003). More recently, these cells have been expanded and
matured by addition of HGF and OSM (Hay et al., 2008b). DMSO
can similarly affect histone acetylation and promote hepato-
cyte-like differentiation (Hay et al., 2007). Mechanistically, it
remains unclear why such widespread epigenetic modulation
can be effective leading to these agents being termed
unspecific (Sharma et al., 2006; Zhou et al., 2007).
Lineage tracing to enrich for hepatocyte-like differentiation
from embryonic stem cells
Despite the improvements made to protocols in differentiating
hepatocyte-like cells from PSCs, cultures remain heteroge-
neous. Therefore, many strategies have built in the use of PSCs
capable of expressing stably transfected fluorescent reporter
genes (e.g. enhanced green fluorescent protein (EGFP)) under
the control of a liver-specific promoter or enhancer, commonlyfrom the AFP, ALB or α1-antitrypsin (AAT, officially known as
SERPINA10) genes (Duan et al., 2007; Lavon et al., 2004; Ishii et
al., 2008). This has allowed real-time tracking of differentiating
cultures, tracing of transplanted cells in vivo and the selection
of appropriately differentiated cells by FACS (Basma et al.,
2009). AFP expression reflects hepatocyte maturity: it is
abundantly expressed in the fetal liver, but is extinguished in
adult hepatocytes and only re-expressed as a marker of
regeneration or hepatocellular carcinoma (Chen et al., 1997;
Lopez, 2005). In keeping with this profile, hepatocyte-like cells
selected by AFP reporter gene expression exhibited no mature
hepatocyte function beyond ALB secretion (Duan et al., 2007;
Ishii et al., 2008; Chiao et al., 2008). In contrast, AAT is
expressed in hepatocyte progenitors and mature hepatocytes.
Enrichment of hepatocyte-like cells differentiated from ESCs
and EB outgrowth cultures by selecting for lentiviral expression
of an AAT-EGFP transgene exhibited liver-specific functions
such as CYP activity, and indocyanine green dye (ICG) uptake
and secretion, as well as hepatic gene and protein
expression (Duan et al., 2007). In this study, following random
differentiation of plated EBs up to 14% of cells expressed EGFP
and, surprisingly, exhibited CYP1A2 activity comparable to
primary human hepatocytes (Duan et al., 2007).
Characterisation and analysis of hepatocyte-like cells
derived from embryonic stem cells
A summary of characterisation from different studies is
provided in Table 2. The initial formation of definitive
endoderm has been characterised by the transient expression
of the primitive streakmarker Brachyury, and a combination of
FOXA2, GATA4 and SOX17; (D'Amour et al., 2005) (Fig. 5). The
subsequent generation of hepatoblasts has been defined by
ALB and AFP expression (Soto-Gutierrez et al., 2007). More
mature hepatocyte-like cells, suggested by characteristic
epithelial morphology, have been described according to
immunostaining for a combination of ALB along with CK18,
and transcription factors, such as HNF4α, CEBPα and CEBPβ, in
the absence of AFP (Duan et al., 2007; Monaghan et al., 1993;
Baharvand et al., 2008). Similar status has been inferred by
expression of a range of liver-specific enzymes such as CYPs,
TAT and AAT (Duan et al., 2007; Cai et al., 2007; Zhao et al.,
2009). In some studies, functional characteristics have been
obtained. During repair following liver injury, transplanted
ESC-derived hepatocyte-like cells carried a selective advan-
tage (Shafritz and Dabeva, 2002), and have been shown to
integrate and differentiate into hepatocytes in host liver
(Gouon-Evans et al., 2006; Agarwal et al., 2008), secrete ALB
and AAT (Duan et al., 2007; Basma et al., 2009), improve
hepatic function and increase survival rates (Soto-Gutierrez et
al., 2006; Ishii et al., 2007). Similarly, their use in bioartificial
liver devices improved short-term (5-day) survival rates of rats
with fulminant hepatic failure (Cho et al., 2008).
Unmet demands and future challenges for
hepatocyte-like cells generated from pluripotent
stem cells
Despite the initial progress, there remain several short-
comings and barriers to the use of cells currently derived
from human PSCs as a toxicity screening platform during drug
discovery.
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like cells
At present the characterisation of hepatocyte-like cells
generated from human PSCs has tended to reflect the
hypothesis-driven experimentation of individual, indepen-
dent research laboratories. Most protocols have described
the appearance of cells with typical hepatocyte morphology,
however, there has been a general lack of agreed standards,
equivalent for instance to the ‘minimum information about a
microarray experiment (MIAME)’ parameters required to
deposit expression microarray data in public repositories
(Brazma, 2009; Brazma et al., 2001). In redress, Sancho-Bru
et al. have made very helpful recommendations for the
characterisation of stem cell derived hepatocyte-like cells
(Sancho-Bru et al., 2009), highlighting minimal criteria by
which different protocols can be compared. In Table 1A, we
also provide a profile of gene expression, reliant on both
positive and negative markers, attempting to discriminate
hepatocyte-like and biliary-like cells from other cell-types.
Themajor problem is that genes expressed during hepatocyte
differentiation are also commonly expressed in other organs
and tissues (e.g. AFP in extra-embryonic endoderm (Gualdi et
al., 1996), and FOXA2 in other endodermal and ectodermal
tissues (Neta Lavon, 2005). Analysing the origin of human
expressed sequence tags (ESTs) in the Unigene database
reinforces this scale of this problem: only 21% of ESTs for
human AFP originated from liver; most came from human
fetal heart librariesmaking the inclusion of ‘negative control’
genes, such asMLC2V, particularly important (Table 1A). This
issue can compromise differentiation strategies reliant on
reporter genes expressed under the control of regulatory
elements from a single ‘hepatocyte-specific’ gene (Soto-
Gutierrez et al., 2006; Duan et al., 2007; Ishii et al., 2007).
Where AFP-positive cells have been selected via reporter
gene expression, other hepatocytemarkers including TAT and
tryptophan 2,3-dioxygenase (TDO2) have been weakly
detected and albumin has only been expressed in a minority
of cells, suggestive of significant extra-embryonic differen-
tiation (Ishii et al., 2008).
When it comes to mature hepatocytes, commonly used
markers can also be expressed in other tissues, for example
HNF4α in the kidney, pancreas, testis and intestine (Drewes
et al., 1996). However, highly restricted gene expression
profiles are available for mature hepatocytes. Although CYPs
are surprisingly widely expressed, all bar one human EST for
the organic anion transporter OATP2 (officially known as
SLCO1B1) and AAT (officially known as SERPINA10), arose
from liver (the others were from breast and fetal heart,
respectively). When coupled to the expression of other
markers, like TDO2 and TAT, it is possible to clearly define the
human hepatocyte by the expression of surprisingly few
genes. The same does not appear true of the biliary epithelial
cell, where greater reliance on the absence of negative
markers becomes important (Table 1A).
Functional attributes of hepatocyte-like cells for
drug toxicity platforms
Whereas thorough gene expression profiling may indicate a
cell's lineage and ‘baseline’ phenotype, it is in vitro mimicryof dynamic hepatocyte function that is paramount for
effective NCE toxicity screening during drug discovery.
Alongside the widely appreciated importance of inducible
CYP activity, this also includes albumin secretion, urea
synthesis, glycogen storage, and uptake and excretion of ICG
(Duan et al., 2007; Agarwal et al., 2008; Hay et al., 2007; Cho
et al., 2008) (Table 1B-C). However, as with gene expression
profiling, some of these attributes in isolation are not
hepatocyte-specific; for instance, undifferentiated ESCs, as
well as myocytes, can also accumulate intracellular glycogen
deposits (Johkura et al., 2004).
Given the importance of CYP activity for drug inactiva-
tion, pro-drug activation or the generation of toxic
metabolites, assessment of these enzymes in PSC-derived
hepatocyte-like cells is critical and, as yet, incomplete. No
studies to date have demonstrated adequate CYP induction
in PSC-derived hepatocyte-like cells in response to known
reference compounds (Tables 1C and 2). Whereas some
studies of human PSC-derived hepatocyte-like cells have
detected CYP transcripts, such as CYP7A1 and CYP3A4, by
RT-PCR (Duan et al., 2007; Hay et al., 2008a), actual enzyme
concentrations have rarely been quantified and / or activity
is often not equated to the gold standard of freshly isolated
human primary hepatocytes (Hay et al., 2007); although
providing preliminary clues, less helpful comparisons have
been made to undifferentiated ESCs or hepatocyte cell lines
with limited CYP activity (e.g. HepG2) (Hay et al., 2008a;
Novik et al., 2008; Wilkening et al., 2003; Hewitt and
Hewitt, 2004; Rodrã­Guez-Antona et al., 2002; Ek et al.,
2007). Certainly, very few protocols have described CYP
activity that is near-comparable to that of adult hepato-
cytes (Duan et al., 2007) (with care to ensure no loss of
enzyme activities in the latter during in vitro culture
(Jasmund et al., 2007).Purity of hepatocyte-like differentiation versus the
value of multi-cellular complexity
A mixed population comprising only a small proportion of
hepatocyte-like cells could be responsible for the low levels
of enzyme activity that have been reported to date from
differentiated PSC cultures (Hay et al., 2008b). Indeed,
hepatocyte differentiation, determined by FACS analysis for
more than one marker (Gouon-Evans et al., 2006), seems
inefficient (between 10-30%) (Hay et al., 2007; Basma et al.,
2009) making subsequent enrichment steps necessary. Basma
et al. described cell selection via detection of asialoglyco-
protein receptor (ASGPR) yielding cells with levels of
CYP1A1/CYP1A2, AAT, complement factor VII (CFVII) activity
and urea comparable to primary hepatocytes (Basma et al.,
2009).
The opposite perspective from trying to isolate pure
hepatocyte-like cells is to actively encourage protocols
that incorporate other liver cell-types thereby trying to
create a more complete in vitro mimic of physiological
liver function. Progress has been made in reporting biliary-
like epithelial differentiation by modifying methodology
after the specification of hepatoblasts (Zhao et al., 2009).
Other important cell-types to consider include hepatic
stellate cells as a model for agents capable of inducing
liver fibrosis.
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cells derived from pluripotent stem cells
Primary hepatocytes undergo limited expansion ex vivo
before they lose their mature cell phenotype even with
manipulations such as collagen or Matrigel overlay (Elaut et
al., 2006; Jasmund et al., 2007). Therefore, it seems
reasonable to predict that PSC-derived hepatocyte-like
cells will undergo similar dedifferentiation. This poses
questions as to when to harvest a population of hepato-
cyte-like cells differentiated from PSCs: if the mature
phenotype is only transient, attaining pure mature popula-
tions seems unlikely unless PSC differentiation is synchro-
nised. A more likely endpoint would be heterogeneous PSC-
derived cells at different stages of hepatocyte-like maturity.
Synchronising differentiation is technically difficult if not
biologically impossible; even undifferentiated ESC cultures
are heterogeneous for critical transcription factors such as
Nanog (Chambers et al., 2007). Furthermore, colonies of ESC
are not uniform and often consist of a peripheral margin of
spontaneously differentiated cells (Johkura et al., 2004).
Scale-up is mandatory for practical use by the pharmaceu-
tical industry. The expansion of the differentiated, mature
hepatocytes is technically difficult but the expansion of
hepatic progenitor cells could be more achievable. ESC-
derived bipotential hepatic progenitors have been expanded
for more than 100 days whilst maintaining their phenotype in
terms of gene expression and the capacity to differentiate into
hepatocytes and biliary epithelial cells (Zhao et al., 2009).
However, the ability of the former cells to induce CYP activity
in response to reference compounds was not compared to
human adult hepatocytes.
Using hepatocyte-like cells derived from pluripotent
stem cells for in vivo drug testing
In vitro liver cell models have their limitations in terms of
preserving the activity and maturity of the hepatocyte
phenotype; an alternative would be an in vivo, artificial
human liver for testing NCEs (Yoshizato and Tateno, 2009).
Several models of mouse chimeras with humanized livers have
been described. For instance, the chimeric urokinase-type
plasminogen activator (uPA)+/+/severe combined immunode-
ficient (SCID) transgenic mouse line in which the liver can be
over 90% repopulated with human hepatocytes (Katoh et al.,
2008). These humanizedmiceexpress humanphase I andphase
II enzymes and exhibit humanized drug metabolism (Katoh et
al., 2008). As such they are a powerful model for pre-clinical
drug development. Potentially, the uPA+/+/SCID mouse liver
could be repopulated with PSC-derived hepatocyte-like cells
to exhibit a metabolic capacity reflective of the particular
genotype of the human cells.
In vivo transplantation of PSC-derived liver cells might also
solve the problem of generating fully functional, mature
hepatocytes in vitro. The engraftment of ESC-derived pancre-
atic endoderm cells, resembling immature, fetal pancreatic
tissue into SCID mice facilitated their final differentiation and
maturation. Results showed that threemonths post-transplan-
tation the implant contained glucose-responsive insulin-
secreting cells that were functionally very similar to trans-
planted adult human islets (Kroon et al., 2008). Similarly,transplantation of PSC-derived hepatocyte-like cells might
promote their fullmaturation. To date, such experiments have
resulted in low and transient integration of the human cells,
even when they have a proliferative advantage over the host
cells (Duan et al., 2007; Agarwal et al., 2008; Ishii et al., 2007),
however, in vivo maturation might be achievable by implant-
ing cells on a bioartificial liver device as reported by Soto-
Guiterrez et al. (Soto-Gutierrez et al., 2006). Furthermore,
although there is potential for a high degree of humanization
of mouse models there would still remain the underlying
species differences either from the remaining murine hepato-
cyte complement or from other murine-specific effects.
Ensuring the necessary genetic diversity
There is increasing evidence that different ESC lines exhibit
differing propensities for differentiation into specific lineages
(Osafune et al., 2008), including hepatocytes (Ek et al., 2007).
As such, a direct comparison between hepatocyte differenti-
ation methods is often difficult because different protocols
have been developed using different ESC lines. However, with
better differentiation protocols and future iPSC lines, it seems
feasible to anticipate panels of hepatocyte-like cells repre-
senting the different genotypes that underlie varying drug
metabolising phenotypes. This is similar in principle to HLA
matching of potential ESC derived transplants,where up to150
selected different PSC lines have been estimated to be
necessary (Taylor et al., 2005). The use of iPSC-derived
hepatocytes would also avoid the ethical issues for some from
the use of ESC, however the complete replacement of ESCwith
iPSCmust be carefully considered. For instance, iPSC lines that
have been reprogrammed using retroviruses may exhibit
abnormal gene expression depending on the location of the
retroviral insertion sites. There is also evidence that iPSC
exhibit residual somatic gene expression from their originating
cell type (Ghosh et al., 2010). As such, in our opinion, ESCs
currently remain the archetypal PSC from which to generate
liver cell models.
Other commercial considerations and practicalities
Whereas the above details a number of major barriers that
will need surmounting for human PSCs to be applied as drug
toxicity platforms, other issues will influence potential take-
up by the pharmaceutical industry. These matters include
robustness, ease of use, avoidance of inactivated feeder
layers, cryopreservation, survival after shipping and batch-
to-batch consistency.
Summary
There has nowbeen almost a dozen years of fruitful human ESC
research (Thomsonet al., 1998; D'Amour et al., 2006; Lamba et
al., 2009; Kim et al., 2007; Baker et al., 2007). Rapid progress
has occurred during this short time, largely in the arena of
discovery science. It is relatively easy to predict that the next
ten years will begin translation of this basic knowledge into
clinical applications for human benefit. The potential for
better hepatotoxicity platforms to test NCEs is exciting; the
challenge now is to close the gap between hypothesis-driven
18 M.A. Baxter et al.research and pharmaceutical industry requirements, moving
from differentiating the first hepatocyte-like cells in a dish to
generating high-throughput platforms and standard operating
procedures that are widely attainable in a cost-effective,
efficacious manner.
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